Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results and corporate update for the three months ended March 31, 2020. Based on current operations, we expect that cash on hand and available capital provide the Company with sufficient resources to fund all planned Company operations including research and development into 2022. CG-806 has, thus far, materialized as resilient to the COVID-19 disruptions because of its profile as a safe, orally administered agent directed at critically ill patients with hematologic malignancies and because of the sites chosen for our clinical studies.
Guru invests in restructuring cancer drug developer Continue reading...
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for January 29th
Investors seeking out high growth for their portfolios will often turn to biotech stocks. The biotechnology industry, which has become densely populated as our understanding of living systems and organisms continues to expand, has earned a reputation on Wall Street for its explosive potential ... and high volatility.In contrast to companies in other sectors, the gains and losses in even the best biotech stocks hinge less on earnings results, and more on a few key indicators such as trial-data readouts or verdicts from regulatory agencies. Product approvals unlock vital revenues, so a single positive update can function as a catalyst that propels shares to new highs.Of course, there's a reason risk-averse investors shy away from these stocks: The opposite also holds true.Wall Street pros rightly advise a cautious approach when evaluating the biotechnology industries. We find that monitoring the analyst community can be helpful on a couple fronts: For one, we can see where the pros are putting their faith. Also, analysts can provide much-needed insight into many stocks that get little media coverage, and whose progress can be difficult to gauge unless you're a medical expert.We used TipRanks' Stock Screener tool to comb through hundreds of biotechnology stocks to identify promising picks - ones that have received enough lopsided support from analysts that they earn TipRanks' top Strong Buy consensus rating. Here, we have found five top biotech stocks with overwhelmingly bullish sentiment from the analyst community, and price-growth projections of between 28% and 82%. SEE ALSO: 8 Stock Picks Getting Hit by Coronavirus Fears
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Aptose Biosciences, Inc. (NASDAQ:APTO) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 5, 2020 at 5:00 PM ...
SAN DIEGO and TORONTO, April 27, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target.
Investors weren't excited by the biotech's preliminary results from an early-stage clinical study.
SAN DIEGO and TORONTO, May 14, 2020 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the year and three months ended December 31, 2019 and reported on corporate developments. Based on current operations, we expect that cash on hand and available capital provide the Company with sufficient resources to fund all planned Company operations including research and development into early 2022.
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced today that it has filed its proxy statement for the 2020 annual general meeting of shareholders. The annual general meeting of Aptose shareholders will be held on June 2, 2020 at 10:00 a.m. Pacific time in an online only format. There will be no physical location for shareholders and duly appointed proxyholders to attend.
SAN DIEGO and TORONTO, Jan. 29, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
APTO earnings call for the period ending March 31, 2020.
We can readily understand why investors are attracted to unprofitable companies. For example, Aptose Biosciences...
SAN DIEGO and TORONTO, April 21, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target.
SAN DIEGO and TORONTO, Feb. 25, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
Does Aptose Biosciences (APTO) have what it takes to be a top stock pick for momentum investors? Let's find out.
SAN DIEGO and TORONTO, May 07, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced that it has entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Sandler and Canaccord Genuity (collectively “Agents”). Under the terms of the Equity Distribution Agreement, the Company may, from time to time, issue and sell through the Agents, common shares of the Company (the “Common Shares”) through “at-the-market” (“ATM”) distributions (the “Offering”) on the Nasdaq Capital Market (“NASDAQ”).
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.